Shares of Eli Lilly and Company (NYSE:LLY) have received a consensus rating of “Hold” from the twenty brokerages that are currently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $90.09.

LLY has been the subject of several analyst reports. Jefferies Group restated a “buy” rating and issued a $89.00 target price on shares of Eli Lilly and in a research note on Monday, September 11th. BMO Capital Markets restated an “underperform” rating and issued a $71.00 target price (down previously from $73.00) on shares of Eli Lilly and in a research note on Wednesday, September 6th. Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and raised their price target for the company from $84.23 to $88.00 in a report on Tuesday, October 10th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $105.00 price target (up previously from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a report on Thursday, October 26th.

Shares of Eli Lilly and (NYSE LLY) traded up $0.63 during midday trading on Thursday, reaching $86.71. The company’s stock had a trading volume of 4,027,559 shares, compared to its average volume of 3,280,000. Eli Lilly and has a fifty-two week low of $72.68 and a fifty-two week high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The company has a market cap of $95,480.00, a P/E ratio of 21.17, a P/E/G ratio of 1.79 and a beta of 0.35.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter last year, the company earned $0.88 EPS. The firm’s revenue was up 9.0% compared to the same quarter last year. equities research analysts predict that Eli Lilly and will post 4.22 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.59%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is presently 99.05%.

In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares in the company, valued at $4,729,989.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 651,088 shares of company stock worth $56,439,586. Insiders own 0.20% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Advantus Capital Management Inc increased its stake in Eli Lilly and by 0.4% in the 1st quarter. Advantus Capital Management Inc now owns 97,698 shares of the company’s stock worth $8,217,000 after purchasing an additional 425 shares during the period. Modera Wealth Management LLC purchased a new position in Eli Lilly and in the 1st quarter worth approximately $238,000. Partnervest Advisory Services LLC increased its stake in Eli Lilly and by 12.4% in the 1st quarter. Partnervest Advisory Services LLC now owns 5,820 shares of the company’s stock worth $489,000 after purchasing an additional 643 shares during the period. Stephens Inc. AR increased its stake in Eli Lilly and by 4.5% in the 1st quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock worth $3,703,000 after purchasing an additional 1,901 shares during the period. Finally, Bellevue Group AG increased its stake in Eli Lilly and by 275.4% in the 1st quarter. Bellevue Group AG now owns 131,400 shares of the company’s stock worth $11,052,000 after purchasing an additional 96,400 shares during the period. 76.30% of the stock is currently owned by institutional investors.

WARNING: “Eli Lilly and Company (LLY) Receives $90.09 Consensus Price Target from Brokerages” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/eli-lilly-and-company-lly-receives-90-09-consensus-price-target-from-brokerages/1773591.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.